Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems

Recently, the U.S. Food and Drug Administration (FDA) approved the first oral antiviral drug to treat mild to moderate cases of coronavirus disease. The combination of nirmatrelvir with an already used protease inhibitor class drug, ritonavir, has led to Paxlovid®. Several studies considered drug re...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira Pinheiro, Lucas Barboza, Tao, Songsheng, Culbertson, Elizabeth, Lima Barros de Araujo, Gabriel, Billinge, Simon J.L., Ferreira, Fabio Furlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585847/
https://www.ncbi.nlm.nih.gov/pubmed/36280220
http://dx.doi.org/10.1016/j.ijpharm.2022.122329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585847/
https://www.ncbi.nlm.nih.gov/pubmed/36280220
http://dx.doi.org/10.1016/j.ijpharm.2022.122329

Ejemplares similares